Whitfield Represents AbbVie on Acquisition of Allergan for $63 Billion

Press Release   ·   25 June 2019

Overview

The source reports Abb Vie’s agreement to acquire Allergan through a cash-and-share transaction.

Transaction value

The announcement gives an equity value of approximately $63 billion, rather than treating that amount as an enterprise valuation.

Business combination

It describes a combined pharmaceutical portfolio spanning immunology, oncology, aesthetics, neuroscience, women’s health, eye care and virology.

Announcement status

The article originally anticipated an early 2020 close subject to regulatory approvals. Eric Schiele, Jonathan Davis and Carlo Zenkner are identified among corporate leads, with additional finance, compensation, competition, tax and healthcare specialists listed in the source.